Phase III COMPASS study with Bayer ’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early (for specialized target groups only)

Coronary or peripheral artery disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke / Rivaroxaban is the only non-vitamin K antagonist oral anticoagulant currently under assessment in this high risk patient population
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news